Rare Tumors: Opportunities and Challenges From the Children's Oncology Group Perspective

Authors

Kris Ann Schultz, Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN.
Murali Chintagumpala, Division of Hematology-Oncology, Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX.
Jin Piao, University of Southern California Keck School of Medicine, Los Angeles, CA.
Kenneth S. Chen, Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX.
Rachana Shah, University of Southern California Keck School of Medicine, Los Angeles, CA.
Robyn D. Gartrell, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Columbia University Irving Medical Center, New York, NY.
Emily Christison-Lagay, Yale School of Medicine, Yale New-Haven Children's Hospital, New Haven, CT.
Farzana Pashnakar, Department of Pediatrics, Yale University School of Medicine, New Haven, CT.
Jesse L. Berry, University of Southern California Keck School of Medicine, Los Angeles, CA.
Allison F. O'Neill, Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Department of Pediatric Oncology, Boston, MA.
Lauren M. Vasta, Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD.
Ashley Flynn, Hematology/Oncology, Children's Mercy Kansas City, Kansas City, MO.
Sarah G. Mitchell, Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.
Brittani Kn Seynnaeve, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Jeremy Rosenblum, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Westchester Medical Center, New York Medical College, Valhalla, New York, NY.
Samara L. Potter, The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Junne Kamihara, Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Department of Pediatric Oncology, Boston, MA.
Carlos Rodriguez-Galindo, Departments of Global Pediatric Medicine and Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Douglas S. Hawkins, Division of Hematology-Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA.
Theodore W. Laetsch, Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA.

Author Type(s)

Faculty

DOI

10.1016/j.ejcped.2023.100024

Journal Title

EJC Paediatric Oncology

Document Type

Article

Publication Date

12-1-2023

Department

Pediatrics

Abstract

While all childhood cancers are rare, tumors that are particularly infrequent or underrepresented within pediatrics are studied under the umbrella of the Children's Oncology Group Rare Tumor committee, divided into the Retinoblastoma and Infrequent Tumor subcommittees. The Infrequent Tumor subcommittee has traditionally included an emphasis on globally rare tumors such as adrenocortical carcinoma, nasopharyngeal carcinoma, or those tumors that are rare in young children, despite being common in adolescents and young adults, such as colorectal carcinoma, thyroid carcinoma, and melanoma. Pleuropulmonary blastoma, gonadal stromal tumors, pancreatic tumors including pancreatoblastoma, gastrointestinal stromal tumor, nonmelanoma skin cancers, neuroendocrine tumors, and desmoplastic small round cell tumors, as well as other carcinomas are also included under the heading of the Children's Oncology Group Rare Tumor committee. While substantial challenges exist in rare cancers, inclusion and global collaboration remain key priorities to ensure high quality research to advance care.

Recommended Citation

Schultz, K. A., Chintagumpala, M., Piao, J., Chen, K. S., Shah, R., Gartrell, R. D., Christison-Lagay, E., Pashnakar, F., Berry, J. L., O'Neill, A. F., Vasta, L. M., Flynn, A., Mitchell, S. G., Seynnaeve, B. K., Rosenblum, J., Potter, S. L., Kamihara, J., Rodriguez-Galindo, C., Hawkins, D. S., & Laetsch, T. W. (2023). Rare Tumors: Opportunities and Challenges From the Children's Oncology Group Perspective. EJC Paediatric Oncology, 2. https://doi.org/10.1016/j.ejcped.2023.100024